SecBot SecBot
ANALYST-UPGRADE ·Filed Oct 1, 2026

REGN

REGENERON PHARMACEUTICALS, INC.
BULLISH
Impact 4/10
Horizonmonths Processed1mo ago SECanalyst-REGN-argusres-20261001
Argus Research double upgrade: Hold → Buy
Actionable Insight ▲ Bullish

The double upgrade from Argus aligns with a strongly bullish consensus and positive EPS revision momentum, but significant insider selling and institutional trimming create a conflicting signal. The setup is constructive but warrants caution given the divergence between analyst optimism and insider behavior.

DirectionBullish
Confidencemedium
Horizonmonths

Price Chart

Loading chart...

Executive Summary

Argus Research issued a double upgrade on Regeneron Pharmaceuticals (REGN) on October 1, 2026, raising its rating from Hold to Buy with a new price target of $850. The stock currently trades at $758.27, implying approximately 12.1% upside to the new target. Argus has a 54% accuracy rate on 377 scored calls with an average return of 3.3%, placing it in the middle of the pack among firms covering REGN. The consensus on REGN is heavily bullish, with 26 analysts split at 100% Buy (26 Buy/Strong Buy) and 0% Hold or Sell. The mean price target is $850.88, nearly identical to Argus's $850 target, indicating this call is closely aligned with consensus. Momentum is positive, with 1 upgrade and 0 downgrades in the past 30 days, and EPS estimates for the current fiscal year have seen 23 upward revisions versus 0 downward revisions over the same period. Insider selling has been notable, with five transactions totaling over $3.3 million in August and September 2026, while institutional activity shows significant trimming by major holders. The next earnings report is due October 30, 2026, adding a near-term catalyst. Overall, the double upgrade reinforces the bullish consensus but is partially offset by insider selling and institutional exits.

Impact Score

Base Score
2/7
LLM Adjustment
+1
Final Score
4/10

Consensus & Targets

Buy / Strong Buy
26 (68%)
Hold
12
Sell / Strong Sell
0
Total Analysts
26
Mean PT
$850.88
Median PT
$857.00
High PT
$1,030.00
Low PT
$730.00
Current Price
$758.27
Implied Upside
+12.2%

The consensus among 26 analysts covering REGN is overwhelmingly bullish: 8 Strong Buy, 18 Buy, 12 Hold, 0 Sell, 0 Strong Sell. This translates to 100% Buy/Strong Buy and 0% Hold/Sell, making the consensus direction strongly positive. Argus's upgrade aligns with this bullish consensus.

The current price is $758.27. The mean price target is $850.88, median $857, high $1,030, and low $730. The implied upside to the mean is 12.2%. Argus's $850 target is slightly below the mean and median, placing it in the middle of the consensus range.

Recent Analyst Activity

DateFirmActionRatingPrice Target
2026-10-01Argus ResearchupgradeBuy$850.00
2026-09-29RBC CapitalreiterateSector Perform$737.00
2026-09-10HSBCmaintainBuy$920.00
2026-08-17Leerink PartnersmaintainMarket Perform$824.00
2026-08-03CitigroupmaintainNeutralNo target
2026-08-03GuggenheimmaintainBuy$1,030.00
2026-07-31RBC CapitalmaintainSector Perform$737.00
2026-07-31Morgan StanleymaintainEqual-Weight$758.00
2026-07-31Cantor FitzgeraldmaintainOverweight$795.00
2026-07-31Wells FargomaintainEqual-Weight$750.00

In the past 30 days, there has been 1 upgrade (Argus) and 0 downgrades. EPS revision trends are strongly positive: for the current fiscal year (0y), there have been 23 upward revisions and 0 downward revisions in the past 30 days. Estimates are being revised higher across all near-term periods, supporting the bullish analyst momentum.

Firm Track Record: Argus Research

Argus Research accuracy: 54% on 377 calls | avg return: 3.3%

Industry benchmark: mean 51% ± 10%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.

FirmAccuracyCallsAvg Returnvs Average
UBS67%4/65.1%top tier
Canaccord Genuity57%4/79.4%above average
TD Cowen50%1/23.1%below average
Bernstein50%1/26.2%below average
Cantor Fitzgerald50%4/8-4.5%below average
BMO Capital50%3/6-3.7%below average
Morgan Stanley50%5/104.1%below average
Goldman Sachs50%1/2-3.6%below average
Leerink Partners50%1/2-23.7%below average
Evercore ISI Group50%1/2-4.9%below average

Argus Research has a 54% accuracy rate on 377 scored calls with an average return of 3.3%. This places it in the middle tier among firms covering REGN. The best-performing firm is Canaccord Genuity (57% accuracy, 9.4% avg return), while the worst is Leerink Partners (50% accuracy, -23.7% avg return). Argus's accuracy is slightly above the average of the firms listed.

Earnings Estimates

Next earnings: Oct 30, 2026

PeriodEPS Est.EPS RangeRevenueRevisions (7d)
+1q$15.53$10.47 to $18.62$4.6B↑0 ↓0
0q$15.94$14.53 to $17.68$4.5B↑0 ↓0
0y$54.10$43.42 to $59.45$17.0B↑2 ↓0
+1y$50.63$42.52 to $57.25$18.5B↑0 ↓0

Cross-Platform Signals

Insider Trades (90d)
0 buys / 5 sells
Congressional
Ro Khanna (democrat): buy $1,001 - $15,000
Institutional
PRICE T ROWE ASSOCIATES INC /MD/: trim (-29.8%)
Institutional
Capital Research Global Investors: exit (-100%)
Institutional
Capital World Investors: trim (-42.6%)

Insider trading shows five sell transactions in August-September 2026 totaling over $3.3 million, including sales by directors McCourt Marion and Zoghbi Huda Y. This selling diverges from the bullish analyst signal. Institutional activity shows significant trimming: T. Rowe Price trimmed 29.8%, Capital World Investors trimmed 42.6%, and Capital Research Global Investors exited completely. One small institutional add was noted. Congressional activity shows a buy by Rep. Ro Khanna in July 2026. Short interest data is not available. Overall, the insider and institutional signals diverge from the bullish analyst consensus.

Investment Themes

Documents Analyzed

Report based on filing metadata.

Track record

53 reports on REGN

Performance horizon

11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
  2. Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
  3. Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
  4. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  5. Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  6. Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  7. Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  8. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  10. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
Showing 10 of 53

US Market Status

Market Closed · Opens Wed (10h 40m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 1, 2026